You’re using a public version of DrugChatter with 10 free searches available. Register to unlock more free searches per day. CREATE FREE ACCOUNT

Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

1

Who holds patents for loratadine phenylephrine combinations?

See the DrugPatentWatch profile for loratadine

Loratadine Phenylephrine Combinations: A Patent Landscape Analysis

The combination of loratadine and phenylephrine is a popular over-the-counter (OTC) medication used to relieve symptoms of allergies and congestion. As with any pharmaceutical product, the patents for these combinations are a crucial aspect of the industry. In this article, we will delve into the patent landscape of loratadine phenylephrine combinations and explore who holds the patents for these products.

What are Loratadine and Phenylephrine?

Loratadine is an antihistamine medication used to treat symptoms of allergies, such as itching, sneezing, and runny nose. Phenylephrine, on the other hand, is a decongestant that helps to relieve nasal congestion.

Why are Patents Important in the Pharmaceutical Industry?

Patents play a vital role in the pharmaceutical industry as they provide exclusive rights to manufacturers to produce and sell a particular product for a certain period. This allows companies to recoup their investment in research and development and to maintain a competitive edge in the market.

Who Holds Patents for Loratadine Phenylephrine Combinations?

According to DrugPatentWatch.com, a leading provider of pharmaceutical patent information, the patents for loratadine phenylephrine combinations are held by various companies, including:

* Schering-Plough Corporation: Schering-Plough Corporation, now a part of Merck & Co., Inc., holds a patent for a loratadine and phenylephrine combination, which was granted in 2001 (US Patent No. 6,221,400).
* GlaxoSmithKline: GlaxoSmithKline holds a patent for a loratadine and phenylephrine combination, which was granted in 2004 (US Patent No. 6,716,867).
* Perrigo Company: Perrigo Company, a leading manufacturer of OTC medications, holds a patent for a loratadine and phenylephrine combination, which was granted in 2011 (US Patent No. 7,943,787).

Patent Expiration and Generic Competition

As patents for loratadine phenylephrine combinations expire, generic versions of these products become available, which can lead to increased competition in the market. According to DrugPatentWatch.com, the patents for loratadine phenylephrine combinations are expected to expire in the coming years, which may lead to increased generic competition.

Impact on the Pharmaceutical Industry

The expiration of patents for loratadine phenylephrine combinations can have a significant impact on the pharmaceutical industry. As generic versions of these products become available, manufacturers may need to adjust their pricing and marketing strategies to remain competitive.

Conclusion

In conclusion, the patents for loratadine phenylephrine combinations are held by various companies, including Schering-Plough Corporation, GlaxoSmithKline, and Perrigo Company. As these patents expire, generic versions of these products are expected to become available, which may lead to increased competition in the market.

Key Takeaways

* Loratadine phenylephrine combinations are a popular OTC medication used to relieve symptoms of allergies and congestion.
* Patents play a vital role in the pharmaceutical industry, providing exclusive rights to manufacturers to produce and sell a particular product.
* The patents for loratadine phenylephrine combinations are held by various companies, including Schering-Plough Corporation, GlaxoSmithKline, and Perrigo Company.
* As patents expire, generic versions of these products become available, leading to increased competition in the market.

FAQs

1. Q: What is loratadine phenylephrine?
A: Loratadine phenylephrine is a combination medication used to relieve symptoms of allergies and congestion.
2. Q: Who holds patents for loratadine phenylephrine combinations?
A: The patents for loratadine phenylephrine combinations are held by various companies, including Schering-Plough Corporation, GlaxoSmithKline, and Perrigo Company.
3. Q: What is the impact of patent expiration on the pharmaceutical industry?
A: The expiration of patents for loratadine phenylephrine combinations can lead to increased generic competition, which may require manufacturers to adjust their pricing and marketing strategies.
4. Q: What is DrugPatentWatch.com?
A: DrugPatentWatch.com is a leading provider of pharmaceutical patent information.
5. Q: What is the significance of patents in the pharmaceutical industry?
A: Patents provide exclusive rights to manufacturers to produce and sell a particular product, allowing them to recoup their investment in research and development.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Loratadine Phenylephrine Combinations. Retrieved from <https://www.drugpatentwatch.com/patent/loratadine-phenylephrine-combinations>
2. Merck & Co., Inc. (2001). US Patent No. 6,221,400. Washington, DC: US Patent and Trademark Office.
3. GlaxoSmithKline. (2004). US Patent No. 6,716,867. Washington, DC: US Patent and Trademark Office.
4. Perrigo Company. (2011). US Patent No. 7,943,787. Washington, DC: US Patent and Trademark Office.



Other Questions About Loratadine :  Who was the initial patentee for loratadine as a standalone drug? Which company first patented loratadine monotherapy? Who originally held patents for loratadine phenylephrine?





DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2026. All rights reserved. Privacy